This program is supported by an independent education grant from Pfizer. This online education program has been designed for healthcare professionals globally.
In this online teaching session, leading expert Jeffrey Crawford, MD delves into the landscape of emerging therapeutic innovation in cancer cachexia. Dr. Crawford will evaluate the biological underpinnings of novel targets such as GDF-15/GFRAL, review the latest clinical trial data on targeted agents, demonstrate how to identify and stratify patients for trial eligibility using objective biomarkers, and outline practical strategies for integrating these emerging therapies into multidisciplinary care pathways to optimize weight maintenance, physical function, and treatment tolerance.
Accreditation: 0.75 AMA PRA Category 1 Credit™
Session Highlights
- Mechanistic Insights into Novel Targets: Analyze GDF-15/GFRAL signaling and its role in cachexia pathophysiology
- Clinical Trial Patient Selection: Apply biomarker-driven criteria and trial eligibility frameworks to identify appropriate candidates
- Review of Emerging Agents: Examine efficacy and safety data from late-phase studies of targeted cachexia therapies
- Integration into Practice: Design workflow and multidisciplinary collaboration plans to implement novel therapies within existing care models
Who Should Watch
- Medical Oncologists
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
- Dietitians
- Physiotherapists
- Psychologists
- Palliative Care Specialists
- Internal Medicine Physicians with Oncology Focus
- Clinical Research Coordinators
Presented by
Jeffrey Crawford, MD – is the George Barth Geller Distinguished Professor for Research in Cancer and Professor of Medicine at Duke University, where he is also a member of the Duke Cancer Institute. A medical oncologist, his clinical and research expertise focuses on lung cancer, supportive care, and cancer in the elderly. He has led numerous pivotal clinical trials and has also been a principal investigator in early-phase trials of hematopoietic growth factors and targeted therapies.
Continuing Education Information
This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™; Nurses for ANCC Contact Hours. A statement of participation is available for other healthcare professionals.
Unapproved and/or off-label use disclosure
Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Disclosures
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr. Jeffrey Crawford has disclosed financial relationships within the past 24 months with the following ineligible companies: Actimed, Gen Sci, Pfizer, Tensegrity, AstraZeneca, BioAtla, and Pharmacosmos. These relationships include roles such as scientific advisor, steering committee member, clinical trial site participant, and DSMB member. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. His presentation includes reference to non-FDA uses of drug products and/or devices and their unlabelled indications. We will disclose to the audience when this discussion takes place.
CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.
Activity Accreditation for Health Professions
Physicians
AMA PRA Category 1 Credits™ are available for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.
Current Concepts Institute designates this online activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This continuing education activity is active starting 1st October 2025 and will expire on 1st October 2025. Estimated time to complete this activity: 45 minutes.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.